These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 7286035)
21. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol. Floras JS; Jones JV; Hassan MO; Sleight P Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the effect of pindolol and propranolol on heart rate after acute and chronic administration. Finch MB; O'Connor PC; Harron DW; Shanks RG Br J Clin Pharmacol; 1983 Apr; 15(4):431-4. PubMed ID: 6849778 [TBL] [Abstract][Full Text] [Related]
23. The effect of the beta-adrenoceptor antagonist pindolol on exercise performance. Dhatariya RC; Blowers AJ Br J Clin Pharmacol; 1982 May; 13(5):723-7. PubMed ID: 7082540 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. O'Connor PC; Finch MJ; Harron DW; Meredith PA; McDevitt DG; Shanks RG Br J Clin Pharmacol; 1985 Dec; 20(6):659-67. PubMed ID: 2868744 [TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. Aellig WH J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S16-20. PubMed ID: 6188915 [TBL] [Abstract][Full Text] [Related]
26. Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity. Brodde OE; Schemuth R; Brinkmann M; Wang XL; Daul A; Borchard U Naunyn Schmiedebergs Arch Pharmacol; 1986 Jun; 333(2):130-8. PubMed ID: 2875397 [TBL] [Abstract][Full Text] [Related]
27. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)]. Persson I; Ulrich J Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952 [No Abstract] [Full Text] [Related]
28. Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity. Aellig WH Br J Clin Pharmacol; 1985 Jun; 19(6):775-81. PubMed ID: 2862891 [TBL] [Abstract][Full Text] [Related]
29. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man. McCaffrey PM; Riddell JG; Shanks RG Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Sandberg A; Blomqvist I; Jonsson UE; Lundborg P Eur J Clin Pharmacol; 1988; 33 Suppl():S9-14. PubMed ID: 3371395 [TBL] [Abstract][Full Text] [Related]
32. Effect of beta blockade and intrinsic sympathomimetic activity on exercise performance. Ades PA; Brammell HL; Greenberg JH; Horwitz LD Am J Cardiol; 1984 Dec; 54(10):1337-41. PubMed ID: 6507309 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients. Imai Y; Abe K; Sasaki S; Nihei M; Sekino H; Yoshinaga K Tohoku J Exp Med; 1986 Apr; 148(4):421-38. PubMed ID: 3738908 [TBL] [Abstract][Full Text] [Related]
35. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Channer KS; James MA; MacConnell T; Rees JR Br J Clin Pharmacol; 1994 Jan; 37(1):53-7. PubMed ID: 7908532 [TBL] [Abstract][Full Text] [Related]
36. The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Gugler R; Höbel W; Bodem G; Dengler HJ Clin Pharmacol Ther; 1975 Feb; 17(2):127-33. PubMed ID: 1122674 [TBL] [Abstract][Full Text] [Related]
37. Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. Brodde OE; Wang XL; O'Hara N; Daul A; Schiess W J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S70-3. PubMed ID: 2439825 [TBL] [Abstract][Full Text] [Related]
38. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol. Ishibashi T; Mitomi A; Tatebe S; Imai S Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836 [TBL] [Abstract][Full Text] [Related]
39. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. Garvey HL; Ram N J Pharmacol Exp Ther; 1975 Jul; 194(1):220-33. PubMed ID: 1151751 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of mepindolol sulphate. Bonelli J; Hitzenberger G; Krause W; Wendt H; Speck U Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]